This month the FDA has approved Journavx, a medication that mimics proteins that can help block pain signals from reaching ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

It's the first new type of painkiller in 20 years. And it's just a few weeks away from being here in local pharmacies.

For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

The FDA approved Journavx on Thursday following a pair of clinical trials on 874 participants with moderate to severe acute pain following abdominoplasty — commonly known as a "tummy tuck ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...

Last week, the Food and Drug Administration approved Journavx, the first non-addictive opioid-like pain medication. Scientific discoveries at Yale were key to the development of the drug. Journavx, ...

The drug, which is called suzetrigine and will be sold under the brand name Journavx, is the first new type of pain medicine approved by the agency in more than 20 years. Dr. Jacqueline Corrigan ...

"The approval of JOURNAVX represents a monumental step forward in acute pain treatment," said Ryan Brooks, Chief Executive Officer of CenExel. "For decades, the industry has been searching for a ...